Healthcare provider profile · identity verified

Margaret M Egan, MD

Internal Medicine · JUPITER, FL · NPI 1881602225

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	247	63
Losartan Potassium	Losartan Potassium	238	79
Atorvastatin Calcium	Atorvastatin Calcium	232	69
Rosuvastatin Calcium	Rosuvastatin Calcium	211	76
Lisinopril	Lisinopril	155	47
Amlodipine Besylate	Amlodipine Besylate	146	46
Metoprolol Succinate	Metoprolol Succinate	145	46
Hydrochlorothiazide	Hydrochlorothiazide	129	43
Alendronate Sodium	Alendronate Sodium	122	40
Escitalopram Oxalate	Escitalopram Oxalate	97	34
Simvastatin	Simvastatin	70	24
Omeprazole	Omeprazole	67	26
Gabapentin	Gabapentin	64	22
Eliquis	Apixaban	63	22
Trazodone Hcl	Trazodone Hcl	63	26
Synthroid	Levothyroxine Sodium	62	14
Montelukast Sodium	Montelukast Sodium	56	19
Pantoprazole Sodium	Pantoprazole Sodium	56	19
Methylprednisolone	Methylprednisolone	51	42
Albuterol Sulfate Hfa	Albuterol Sulfate	46	25
Ezetimibe	Ezetimibe	46	12
Azithromycin	Azithromycin	43	39
Furosemide	Furosemide	43	17
Meloxicam	Meloxicam	42	16
Metformin Hcl	Metformin Hcl	39	14
Metoprolol Tartrate	Metoprolol Tartrate	37	11
Potassium Chloride	Potassium Chloride	36	11
Tizanidine Hcl	Tizanidine Hcl	36	20
Fluticasone Propionate	Fluticasone Propionate	34	12
Sertraline Hcl	Sertraline Hcl	34	suppressed
Donepezil Hcl	Donepezil Hcl	33	12
Atenolol	Atenolol	32	suppressed
Clopidogrel	Clopidogrel Bisulfate	29	suppressed
Celecoxib	Celecoxib	28	suppressed
Xarelto	Rivaroxaban	26	suppressed
Alprazolam	Alprazolam	25	12
Fluoxetine Hcl	Fluoxetine Hcl	25	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	25	suppressed
Metformin Hcl Er	Metformin Hcl	24	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	23	suppressed
Citalopram Hbr	Citalopram Hydrobromide	22	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	22	suppressed
Ozempic	Semaglutide	22	suppressed
Valsartan	Valsartan	22	suppressed
Clonidine Hcl	Clonidine Hcl	21	suppressed
Hydralazine Hcl	Hydralazine Hcl	21	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	19	16
Bupropion Xl	Bupropion Hcl	19	suppressed
Carvedilol	Carvedilol	19	suppressed
Famotidine	Famotidine	18	suppressed
Lorazepam	Lorazepam	18	suppressed
Nebivolol Hcl	Nebivolol Hcl	18	suppressed
Ondansetron Hcl	Ondansetron Hcl	16	14
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	16	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	15	suppressed
Methocarbamol	Methocarbamol	15	suppressed
Prednisone	Prednisone	15	11
Ciprofloxacin Hcl	Ciprofloxacin Hcl	14	13
Estradiol	Estradiol	14	suppressed
Tramadol Hcl	Tramadol Hcl	14	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	14	suppressed
Bupropion Hcl Sr	Bupropion Hcl	13	suppressed
Ibandronate Sodium	Ibandronate Sodium	13	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	13	suppressed
Pravastatin Sodium	Pravastatin Sodium	13	suppressed
Sucralfate	Sucralfate	13	suppressed
Allopurinol	Allopurinol	12	suppressed
Creon	Lipase/Protease/Amylase	12	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	12	suppressed
Duloxetine Hcl	Duloxetine Hcl	12	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	12	suppressed
Lansoprazole	Lansoprazole	12	suppressed
Pregabalin	Pregabalin	12	suppressed
Raloxifene Hcl	Raloxifene Hcl	12	suppressed
Tresiba Flextouch U-100	Insulin Degludec	12	suppressed
Trulicity	Dulaglutide	12	suppressed
Doxepin Hcl	Doxepin Hcl	11	suppressed
Eszopiclone	Eszopiclone	11	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	11	suppressed
Mirtazapine	Mirtazapine	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error